Arrhythmia Management

Monitoring and Referral

• The American College of Cardiology recommends considering repeat extended Holter monitoring in 3 months to assess reduction in PACs/PVCs/NSVT burden and correlation with any symptoms that may develop 1
• Cardiology referral should be considered if symptoms develop despite beta-blocker therapy, NSVT episodes become more frequent or prolonged, or beta-blockers are not tolerated, as suggested by the European Heart Journal and the American College of Cardiology 2, 1
• Immediate cardiology referral is necessary for patients with wide complex tachycardia of unknown origin, narrow complex tachycardias with drug resistance or intolerance, Wolff-Parkinson-White syndrome, severe symptoms during palpitations, or irregular palpitations suggesting atrial fibrillation in high-risk patients, as suggested by the American College of Cardiology and the European Heart Journal 3, 1
• Patients with high-risk features, such as syncope or near-syncope with palpitations, family history of sudden cardiac death, or known structural heart disease, require urgent evaluation, as recommended by the American College of Cardiology 3

Diagnostic Evaluation

• 24-hour ambulatory (Holter) monitoring is used to capture arrhythmic events, and is recommended as the first-line diagnostic approach for patients with nighttime palpitations, anxiety, and alcohol use who have mild concentric left ventricular hypertrophy (LVH) and left atrial dilation on echocardiogram, as suggested by the American College of Cardiology 4, 5
• A 12-lead ECG is recommended as an essential diagnostic test (Class I, Level B-NR) to reveal pre-excitation patterns and identify baseline cardiac abnormalities, even if the patient is not currently experiencing symptoms, as suggested by the American College of Cardiology and the European Society of Cardiology 6, 7, 3
• Blood pressure measurement is essential to identify hypertension, as recommended by the American Heart Association 6
• Auscultation is necessary to detect murmurs, bruits, or other abnormal sounds, according to the American College of Physicians 6
• Thyroid function tests should be performed to rule out hyperthyroidism in patients with arrhythmias, as suggested by the American College of Cardiology 8, 9
• Echocardiography is recommended to exclude structural heart disease, particularly in patients with sustained arrhythmias (Class I), as suggested by the American College of Cardiology and the European Society of Cardiology 3, 10, 1

Treatment and Prognosis

• Asymptomatic NSVT with normal cardiac function generally has a favorable prognosis, and the absence of symptoms during documented arrhythmias is reassuring 11
• Beta-blocker therapy is indicated to prevent progression and potential development of symptoms, according to the American College of Cardiology 11
• Beta-blockers (e.g., metoprolol) are the first-line treatment for managing tachycardia, with a target heart rate of <100 bpm or <20% above baseline, as recommended by the American Heart Association and the American College of Cardiology 12, 13, 14, 15
• Calcium channel blockers (non-dihydropyridine, e.g., diltiazem or verapamil) could be considered if beta-blockers are contraindicated or not tolerated, as suggested by the American College of Cardiology 8, 16
• Rhythm control can be achieved with anti-arrhythmic medications, such as amiodarone, or electrical cardioversion, as suggested by the American College of Cardiology and the European Heart Journal 13, 14, 17
• Arterial and venous dilators, including nitrates and phosphodiesterase inhibitors, should be avoided as they can exacerbate symptoms in patients with LVH, and digoxin should also be avoided due to its positive inotropic effects, as suggested by the European Heart Journal 18

Special Populations

• In patients with hypertrophic cardiomyopathy, beta-blockers are recommended to treat palpitations, particularly when associated with left ventricular outflow tract obstruction, as suggested by the European Society of Cardiology 18
• Beta-blockers are recommended to treat palpitations associated with mild tachyarrhythmias or increased adrenergic symptoms in patients with mitral valve prolapse, as suggested by the American Heart Association 19
• Beta-blockers are recommended to treat palpitations associated with anxiety or panic attacks, as suggested by the American Heart Association 19

Lifestyle Modifications

• Lifestyle modifications, including reducing caffeine, alcohol, and smoking, are recommended by the American Heart Association 19
• Reduction or elimination of stimulants such as caffeine, alcohol, and nicotine/smoking may be sufficient to control symptoms in many cases, as suggested by the American Heart Association 15
• Smoking cessation counseling is strongly recommended as smoking exacerbates cardiovascular risk, according to the American College of Cardiology 1

Sleep Apnea

• Sleep disordered breathing is common, occurring in 24% of men and 9% of women, and nocturnal bradyarrhythmias occur in 7.2-40% of sleep apnea patients, as reported in the literature 20
• The following treatment recommendations for sleep apnea are suggested:

• Treatment with continuous positive airway pressure (CPAP) is recommended for patients with sleep apnea, with a Class I, Level B-NR evidence recommendation, as suggested by the American Heart Association 20

Follow-up

• Follow-up in 2 weeks is recommended to assess response to treatment and adjust medication doses as needed based on symptom response, as suggested by the American College of Cardiology 1